An open-label, two-part Phase 2 clinical trial designed to evaluate galeterone in men whose mCRPC rapidly progressed following treatment with either abiraterone or enzalutamide
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2016
At a glance
- Drugs Galeterone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 26 Jul 2016 According to Tokai Pharmaceuticals media release, the company intends to evaluate this planned study following the recommendation made by the independent Data Monitoring Committee (DMC) to discontinue ARMOR3-SV study (Profile 700252262).
- 30 Mar 2016 According to Tokai Pharmaceuticals media release, company is planning to initiate this trial in the middle of 2016.
- 30 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016, as per Tokai Pharmaceuticals media release.